Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100381 | 0.89 | DCUN1D1 (0.39) | GSK3AGSK3BDCUN1D1CNR1LMNA | |
| SCHEMBL5097334 | 0.85 | GSK3B (0.40) | GSK3AGSK3BMAPK14MAPK11DCUN1D1 | |
| SCHEMBL5093625 | 0.84 | GSK3B (0.40) | GSK3AGSK3BMAPK14MAPK13MAPK12 | |
| SCHEMBL5107013 | 0.80 | DCUN1D1 (0.42) | GSK3AGSK3BDCUN1D1CNR1ALPL | |
| SCHEMBL3864560 | 0.79 | MAPK14 (0.39) | MAPK14MAPK11 | |
| SCHEMBL3252473 | 0.78 | GSK3A (0.40) | GSK3AGSK3BMAPK14MAPK13MAPK12 | |
| SCHEMBL4011970 | 0.77 | AURKA (0.47) | GSK3AGSK3BMAPK14DCUN1D1LMNA | |
| SCHEMBL4014215 | 0.77 | MAPK14 (0.58) | GSK3AGSK3BMAPK14MAPK11 | |
| SCHEMBL5100675 | 0.76 | MAPK14 (0.42) | GSK3AGSK3BMAPK14MAPK11CNR1 | |
| SCHEMBL5093570 | 0.76 | CNR1 (0.37) | GSK3AGSK3BMAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | claimed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| EP-1919470-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| WO-2007023105-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023105-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | MAPKAPK2, MAPK1, MAP3K2 | GSK3A 656/4885GSK3B 627/4885MAPK14 33/4885 |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | MAP3K1, MAP3K21, MAP3K2 | GSK3A 2041/4885GSK3B 1767/4885MAPK14 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.